Cara Therapeutics, Inc. Cara Therapeutics, Inc.

Cara Therapeutics, Inc.

CARA

Rang in aandelen #9908
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating... Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Aandeelprijs
$15.96
Laatst gesynchroniseerd: 2025-04-15
Marktkapitalisatie
$875.31M
Verandering (1 dag)
-4.14%
Verandering (1 jaar)
-0.19%
Land
US
Handel Cara Therapeutics, Inc. (CARA)

Categorie

Healthcare
Aandelsplitsingen voor Cara Therapeutics, Inc. (CARA)
Het aandeel Cara Therapeutics, Inc. (symbool: CARA) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 21, 2026.
Eén aandeel CARA dat vóór Oct 21, 2026 werd gekocht, staat nu gelijk aan 0 aandelen CARA.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL